AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 70 filers reported holding AUDENTES THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $39,357,000 | -32.9% | 1,401,119 | -9.5% | 0.01% | -28.6% |
| Q2 2019 | $58,621,000 | -43.1% | 1,548,363 | -41.3% | 0.01% | -41.7% |
| Q1 2019 | $103,005,000 | +53.3% | 2,639,810 | -16.2% | 0.01% | +33.3% |
| Q4 2018 | $67,198,000 | -56.4% | 3,151,884 | -19.1% | 0.01% | -47.1% |
| Q3 2018 | $154,258,000 | -6.8% | 3,896,391 | -10.1% | 0.02% | -10.5% |
| Q2 2018 | $165,520,000 | +9.4% | 4,331,844 | -14.0% | 0.02% | +5.6% |
| Q1 2018 | $151,303,000 | +9.7% | 5,035,067 | +14.1% | 0.02% | +12.5% |
| Q4 2017 | $137,864,000 | +50.4% | 4,411,633 | +34.8% | 0.02% | +45.5% |
| Q3 2017 | $91,665,000 | +1392.7% | 3,272,598 | +919.5% | 0.01% | +1000.0% |
| Q2 2017 | $6,141,000 | +8.9% | 321,000 | -3.0% | 0.00% | 0.0% |
| Q1 2017 | $5,640,000 | -11.8% | 331,000 | -5.4% | 0.00% | 0.0% |
| Q4 2016 | $6,395,000 | +2.6% | 350,000 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $6,234,000 | – | 350,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEXTHERA CAPITAL LP | 294,013 | $11,131,000 | 9.27% |
| GREAT POINT PARTNERS LLC | 1,922,937 | $72,802,000,000 | 8.08% |
| Versant Venture Management, LLC | 553,916 | $20,971,260,000 | 6.11% |
| Foresite Capital Management III, LLC | 315,331 | $11,938,000 | 3.92% |
| Casdin Capital, LLC | 965,000 | $36,534,900,000 | 3.42% |
| Sofinnova Investments, Inc. | 933,640 | $35,348,000 | 3.25% |
| Opaleye Management Inc. | 280,000 | $10,601,000 | 3.23% |
| Redmile Group, LLC | 2,972,167 | $112,526,000 | 3.18% |
| PFM Health Sciences, LP | 3,228,679 | $122,238,000 | 2.32% |
| Eversept Partners, LP | 159,526 | $6,039,654 | 1.69% |